Last reviewed · How we verify
Infex 400 MR
Infex 400 MR is a macrolide antibiotic that inhibits bacterial protein synthesis.
Infex 400 MR is a macrolide antibiotic that inhibits bacterial protein synthesis. Used for Community-acquired pneumonia, Acute exacerbations of chronic bronchitis, Mild to moderate chronic bronchitis.
At a glance
| Generic name | Infex 400 MR |
|---|---|
| Sponsor | Neutec Ar-Ge San ve Tic A.Ş |
| Drug class | Macrolide antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the 50S subunit of the bacterial ribosome, preventing the translocation of peptides during protein synthesis, which ultimately leads to the death of the bacterial cell.
Approved indications
- Community-acquired pneumonia
- Acute exacerbations of chronic bronchitis
- Mild to moderate chronic bronchitis
Common side effects
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |